A5033083939- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Complement system in diseases
- Respiratory viral infections research
- COVID-19 Impact on Reproduction
- Viral gastroenteritis research and epidemiology
- Reproductive System and Pregnancy
- Immunotherapy and Immune Responses
- Kawasaki Disease and Coronary Complications
- Viral Infections and Immunology Research
- COVID-19 epidemiological studies
- SARS-CoV-2 detection and testing
- Cardiac electrophysiology and arrhythmias
- COVID-19 diagnosis using AI
- T-cell and B-cell Immunology
- Pregnancy and Medication Impact
- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- Animal Virus Infections Studies
- Chronic Lymphocytic Leukemia Research
- Long-Term Effects of COVID-19
- Tracheal and airway disorders
- Sperm and Testicular Function
Ragon Institute of MGH, MIT and Harvard
2021-2025
Massachusetts General Hospital
2025
The Omicron variant of SARS-CoV-2 has been shown to evade neutralizing antibodies elicited by vaccination or infection. Despite the global spread variant, even among highly vaccinated populations, death rates have not increased concomitantly. These data suggest that immune mechanisms beyond antibody-mediated virus neutralization may protect against severe disease. In addition pathogens, contribute control and clearance infections through Fc effector mechanisms. Here, we probed ability...
SARS-CoV-2 mRNA vaccines confer robust protection against COVID-19, but the emergence of variants has generated concerns regarding protective efficacy currently approved vaccines, which lose neutralizing potency some variants. Emerging data suggest that antibody functions beyond neutralization may contribute to from disease, little is known about effector functions. Here, we profiled binding and functional capacity convalescent antibodies Moderna mRNA-1273 COVID-19 vaccine-induced across...
Abstract Antibodies serve as biomarkers of infection, but if sustained can confer long-term immunity. Yet, for most clinically approved vaccines, binding antibody titers only a surrogate protection. Instead, the ability vaccine induced antibodies to neutralize or mediate Fc-effector functions is mechanistically linked While evidence has begun point persisting responses among SARS-CoV-2 infected individuals, cases re-infection have emerge, calling protective nature humoral immunity against...
Preexisting cross-coronavirus immunity influences the early development of SARS-CoV-2 humoral after COVID-19.
Although children have been largely spared from coronavirus disease 2019 (COVID-19), the emergence of severe acute respiratory syndrome 2 (SARS-CoV-2) variants concern (VOCs) with increased transmissibility, combined fluctuating mask mandates and school reopenings, has led to infections among children. Thus, there is an urgent need roll out COVID-19 vaccines all ages. However, whether respond equivalently adults mRNA dosing will elicit optimal immunity remain unclear. Here, we aimed deeply...
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP), a passive polyclonal antibody therapeutic agent, has had mixed clinical results. Although neutralization is the predominant approach to benchmarking CCP efficacy, may also influence evolution of endogenous response. Using systems serology comprehensively profile severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) functional antibodies hospitalized people with COVID-19 enrolled in randomized controlled trial...
Therapeutic monoclonal antibodies (mAbs) can be functionally enhanced via Fc engineering. To determine whether pairs of mAbs with different modifications combined for functional complementarity, we investigated the in vitro activity two HIV-1 mAb libraries, each equipped 60 engineered variants. Our findings demonstrate that impact engineering on functionality is dependent specific Fab clone. Notably, combinations variants same specificity exhibited limited enhancement breadth compared to...
The number of mutations in the omicron (B.1.1.529) BA.1 variant concern led to an unprecedented evasion vaccine induced immunity. However, despite rise global infections, severe disease did not increase proportionally and is likely linked persistent recognition by T cells non-neutralizing opsonophagocytic antibodies. Yet, emergence new sublineage BA.2, which more transmissible than relatively preserved neutralizing antibody responses, has raised possibility that BA.2 may evade other...
While children have been largely spared from COVID-19 disease, the emergence of viral variants concern (VOC) with increased transmissibility, combined fluctuating mask mandates and school re-openings led to infections disease among children. Thus, there is an urgent need roll out vaccines all ages. However, whether respond equivalently adults mRNA dosing will elicit optimal immunity remains unclear. Given recent announcement incomplete induced by pediatric dose BNT162b2 vaccine in young...
Currently available mRNA vaccines are extremely safe and effective to prevent severe SARS-CoV-2 infections. However, the emergence of variants concerns (VOCs) has highlighted importance high population-based vaccine rates effectively suppress viral transmission breakthrough While initially left out from efforts, children have become one most affected age groups key targets stop community household spread. Antibodies central for vaccine-induced protection emerging data points additional Fc...
Abstract The introduction of vaccines has inspired new hope in the battle against SARS-CoV-2. However, emergence viral variants, absence potent antivirals, left world struggling with uncertain nature this disease. Antibodies currently represent strongest correlate immunity COVID-19, thus we profiled earliest humoral signatures a large cohort severe and asymptomatic COVID-19 individuals. While SARS-CoV-2-specific immune response evolved rapidly survivors non-survivors exhibited blunted...
Summary COVID-19 convalescent plasma (CCP), a passive polyclonal antibody therapeutic, has exhibited mixed results in the treatment of COVID-19. Given that therapeutic effect CCP may extend beyond ability SARS-CoV-2-specific binding and neutralization to influence evolution endogenous response, we took systematic comprehensive approach analyze SARS-CoV-2 functional profiles participants randomized controlled trial individuals hospitalized with pneumonia where was associated both decreased...
Abstract The number of mutations in the omicron (B1.1.529) BA.1 variant concern (VOC) led to an unprecedented evasion vaccine induced immunity. However, despite remarkable rise global infections, severe disease and death did not increase proportionally, linked persistent recognition by T cells non-neutralizing opsonophagocytic antibodies. Yet, emergence a new sublineage, BA.2, that is more transmissible compared BA.1, relatively preserved neutralizing antibody responses, has raised...
Abstract Currently available mRNA vaccines are extremely safe and effective to prevent severe SARS-CoV-2 infections. However, the emergence of novel variants concerns has highlighted importance high population-based vaccine rates effectively suppress viral transmission breakthrough While initially left out from efforts, children have become one most affected age groups key targets stop community household spread. Antibodies central for induced protection emerging data points additional Fc...
Summary Background SARS-CoV-2 infection is associated with enhanced disease severity in pregnant women. Despite the potential of COVID-19 vaccines to reduce severe disease, vaccine uptake remained relatively low among Just as coordinated messaging from CDC and leading obstetrics organizations began increase confidence this vulnerable group, evolution variants concerns (VOC) including Omicron VOC raised new about efficacy, given their ability escape vaccine-induced neutralizing antibodies....
The robust protection conferred by SARS-CoV-2 mRNA vaccines represents a critical milestone in the COVID-19 vaccine development. However, emergence of variants has inspired renewed concern related to protective efficacy currently approved vaccines, which lose neutralizing potency against some variants. emerging data suggest that antibody functions, beyond neutralization, may contribute from disease. Thus, here we profiled binding and functional capacity convalescent antibodies Moderna...
COVID-19 convalescent plasma (CCP), a passive polyclonal antibody therapeutic, has exhibited mixed results in the treatment of COVID-19. Given that therapeutic effect CCP may extend beyond ability SARS-CoV-2-specific binding and neutralization to influence evolution endogenous response, we took systematic comprehensive approach analyze SARS-CoV-2 functional profiles participants randomized controlled trial individuals hospitalized with pneumonia where was associated both decreased mortality...